Meta-analysis of dengue vaccine effectiveness

Pardomuan Robinson Sihombing

doi:10.55942/pssj.v5i12.1027

Authors

Pardomuan Robinson Sihombing BPS Indonesia https://orcid.org/0000-0002-1597-9077

DOI:

https://doi.org/10.55942/pssj.v5i12.1027

Keywords:

CYD-TDV, dengue vaccine, meta-analysis, vaccine efficacy, TAK-003

Abstract

Dengue hemorrhagic fever has a staggering 390 million cases to date and was the predominant virus in 128 countries in 2022. This study aims to determine vaccination safety and response with respect to negative endpoints over time in the cohort. A systematic review and meta-analysis was performed according to the 2020 PRISMA statement. Comprehensive searches were performed for primary open-access articles in the PubMed and Scopus databases from years 2013-2023. Statistical analysis used random effect modelling a pooled relative risk would be calculated for the efficacy of the vaccine using proportional difference methodology, with 960 articles retrieved (10 articles meeting inclusion criteria incorporated 157,345 study participants) data was arrived in a 2023 publication whereby. The findings were as follows: the tetravalent dengue vaccine had an overall pooled efficacy of 64.6% (95% CI 47.4%-76.2%) and I² 94.7%, with TAK-003 being more efficacious (76.8%, 95% CI 60.8%-86.2%) than CYD-TDV (53.6%, 95% CI 28.9%-69.7%) in symptomatic dengue. The dengue vaccine showed promising efficacy and satisfactory immune response, with TAK-003 showing more consistent performance than CYD-TDV, especially in the absence of heterogeneity between studies. Implications: These findings support the implementation of dengue vaccination with preference for the TAK-003 platform, demonstrating better efficacy consistency to maximize benefits and minimize risk..

Author Biography

Pardomuan Robinson Sihombing, BPS Indonesia

Pardomuan Robinson Sihombing, SST, M.Stat, is a young expert statistician at Statistics Indonesia. He is also a practicing lecturer at several universities. He teaches courses in economic and business statistics, statistical methods, nonparametric statistics, and statistical computing. His research interests include statistical modeling, econometrics, and social statistics.

References

Asish, P. R., Dasgupta, S., Rachel, G., Bagepally, B. S., & Girish Kumar, C. P. (2023). Global prevalence of asymptomatic dengue infections - a systematic review and meta-analysis. International Journal of Infectious Diseases, 134, 292–298. https://doi.org/10.1016/j.ijid.2023.07.010

Biswal, S., Reynales, H., Saez-Llorens, X., Lopez, P., Borja-Tabora, C., Kosalaraksa, P., Sirivichayakul, C., Watanaveeradej, V., Rivera, L., Espinoza, F., Fernando, L., Dietze, R., Luz, K., Venâncio da Cunha, R., Jimeno, J., López-Medina, E., Borkowski, A., Brose, M., Rauscher, M., … Wallace, D. (2019). Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. New England Journal of Medicine, 381(21), 2009–2019. https://doi.org/10.1056/nejmoa1903869

Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M., Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K., Wirawan, D. N., Nallusamy, R., Pitisuttithum, P., Thisyakorn, U., Yoon, I. K., Van Der Vliet, D., Langevin, E., Laot, T., Hutagalung, Y., Frago, C., Boaz, M., … Bouckenooghe, A. (2014). Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet, 384(9951), 1358–1365. https://doi.org/10.1016/S0140-6736(14)61060-6

Dayan, G. H., Garbes, P., Noriega, F., De Sadovsky, A. D. I., Rodrigues, P. M., Giuberti, C., & Dietze, R. (2013). Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. American Journal of Tropical Medicine and Hygiene, 89(6), 1058–1065. https://doi.org/10.4269/ajtmh.13-0304

Diaz-Quijano, F. A., Siqueira de Carvalho, D., Raboni, S. M., Shimakura, S. E., Maron de Mello, A., Vieira da Costa-Ribeiro, M. C., Silva, L., da Cruz Magalhães Buffon, M., Cesario Pereira Maluf, E. M., Graeff, G., Almeida, G., Preto, C., & Luhm, K. R. (2024). Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designs. The Lancet Regional Health - Americas, 35, 100777. https://doi.org/10.1016/j.lana.2024.100777

Ferguson, N. M., Rodríguez-Barraquer, I., Dorigatti, I., Mier-Y-Teran-Romero, L., Laydon, D. J., & Cummings, D. A. T. (2016). Benefits and risks of the sanofi-pasteur dengue vaccine: Modeling optimal deployment. Science, 353(6303), 1033–1036. https://doi.org/10.1126/science.aaf9590

Hadinegoro, S. R., Arredondo-García, J. L., Capeding, M. R., Deseda, C., Chotpitayasunondh, T., Dietze, R., Hj Muhammad Ismail, H. I., Reynales, H., Limkittikul, K., Rivera-Medina, D. M., Tran, H. N., Bouckenooghe, A., Chansinghakul, D., Cortés, M., Fanouillere, K., Forrat, R., Frago, C., Gailhardou, S., Jackson, N., … Saville, M. (2015). Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. New England Journal of Medicine, 373(13), 1195–1206. https://doi.org/10.1056/nejmoa1506223

Johansson, M. A., Hombach, J., & Cummings, D. A. T. (2011). Models of the impact of dengue vaccines: A review of current research and potential approaches. Vaccine, 29(35), 5860–5868. https://doi.org/10.1016/j.vaccine.2011.06.042

Kumbhare, M. R., Chandak, S. M., Dukare, A. B., Kshatriya, V. V., & Velhal, S. S. (2025). An Updated Comprehensive Review of the Dengue Vaccine: Development, Mechanism, Efficacy, and Safety. Journal of Bio-X Research, 8. https://doi.org/10.34133/jbioxresearch.0034

López-Medina, E., Biswal, S., Saez-Llorens, X., Borja-Tabora, C., Bravo, L., Sirivichayakul, C., Vargas, L. M., Alera, M. T., Velásquez, H., Reynales, H., Rivera, L., Watanaveeradej, V., Rodriguez-Arenales, E. J., Yu, D., Espinoza, F., Dietze, R., Fernando, L. K., Wickramasinghe, P., Duarte Moreira, E., … Borkowski, A. (2022). Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. Journal of Infectious Diseases, 225(9), 1521–1532. https://doi.org/10.1093/infdis/jiaa761

Montenegro-Quiñonez, C. A., Louis, V. R., Horstick, O., Velayudhan, R., Dambach, P., & Runge-Ranzinger, S. (2023). Interventions against Aedes/dengue at the household level: a systematic review and meta-analysis. EBioMedicine, 93(June), 104660. https://doi.org/10.1016/j.ebiom.2023.104660

Mora-Rivera, J. (2021). Internet access and poverty reduction: Evidence from rural and urban Mexico. Telecommunications Policy, 45(2). https://doi.org/10.1016/j.telpol.2020.102076

Okoye, E. C., Mitra, A. K., Lomax, T., & Nunaley, C. (2024). Dengue Fever Epidemics and the Prospect of Vaccines: A Systematic Review and Meta-Analysis Using Clinical Trials in Children. Diseases, 12(2). https://doi.org/10.3390/diseases12020032

Orellano, P. W., Salinas, J. L., Reynoso, J. I., Kawamoto, A., & Vazquez-Prokopec, G. (2023). Dengue vaccine acceptance and willingness to pay: A systematic review and meta-analysis. Public Health, 224, 181–190.

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Bmj, 372. https://doi.org/10.1136/bmj.n71

Pangesti, A., Ulfah, B., & Hartono, R. (2023). Investigating the Implementation of IMRaD Structure in Abstracts of Undergraduate Students’ Theses. Pedagogy : Journal of English Language Teaching, 11(2), 109. https://doi.org/10.32332/joelt.v11i2.7144

Rivera, L., Biswal, S., Sáez-Llorens, X., Reynales, H., López-Medina, E., Borja-Tabora, C., Bravo, L., Sirivichayakul, C., Kosalaraksa, P., Vargas, L. M., Yu, D., Watanaveeradej, V., Espinoza, F., Dietze, R., Fernando, L. K., Wickramasinghe, P., Moreira, E. D., Fernando, A. D., Gunasekera, D., … Borkowski, A. (2022). Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003). Clinical Infectious Diseases, 75(1), 107–117. https://doi.org/10.1093/cid/ciab864

Sollaci, L. B., & Pereira, M. G. (2004). The introduction, methods, results, and discussion (IMRAD) structure: A fifty-year survey. Journal of the Medical Library Association, 92(3), 364–367.

Sridhar, S., Luedtke, A., Langevin, E., Zhu, M., Bonaparte, M., Machabert, T., Savarino, S., Zambrano, B., Moureau, A., Khromava, A., Moodie, Z., Westling, T., Mascareñas, C., Frago, C., Cortés, M., Chansinghakul, D., Noriega, F., Bouckenooghe, A., Chen, J., … DiazGranados, C. A. (2018). Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. New England Journal of Medicine, 379(4), 327–340. https://doi.org/10.1056/nejmoa1800820

Torresi, J., Ebert, G., & Pellegrini, M. (2017). Vaccines licensed and in clinical trials for the prevention of dengue. Human Vaccines and Immunotherapeutics, 13(5), 1059–1072. https://doi.org/10.1080/21645515.2016.1261770

Tricou, V., Sáez-Llorens, X., Yu, D., Rivera, L., Jimeno, J., Villarreal, A. C., Dato, E., Saldaña de Suman, O., Montenegro, N., DeAntonio, R., Mazara, S., Vargas, M., Mendoza, D., Rauscher, M., Brose, M., Lefevre, I., Tuboi, S., Borkowski, A., & Wallace, D. (2020). Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial. The Lancet, 395(10234), 1434–1443. https://doi.org/10.1016/S0140-6736(20)30556-0

Villar, L., Dayan, G. H., Arredondo-García, J. L., Rivera, D. M., Cunha, R., Deseda, C., Reynales, H., Costa, M. S., Morales-Ramírez, J. O., Carrasquilla, G., Rey, L. C., Dietze, R., Luz, K., Rivas, E., Miranda Montoya, M. C., Cortés Supelano, M., Zambrano, B., Langevin, E., Boaz, M., … Noriega, F. (2015). Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. New England Journal of Medicine, 372(2), 113–123. https://doi.org/10.1056/nejmoa1411037